Boston Advisors LLC boosted its position in shares of Retrophin Inc. (NASDAQ:RTRX) by 23.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,945 shares of the biopharmaceutical company’s stock after buying an additional 5,185 shares during the period. Boston Advisors LLC’s holdings in Retrophin were worth $480,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of RTRX. Teachers Advisors Inc. raised its position in shares of Retrophin by 14.3% in the first quarter. Teachers Advisors Inc. now owns 231,492 shares of the biopharmaceutical company’s stock valued at $3,162,000 after buying an additional 28,956 shares during the period. BlackRock Fund Advisors raised its position in shares of Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock valued at $17,799,000 after buying an additional 22,903 shares during the period. Spark Investment Management LLC raised its position in shares of Retrophin by 64.2% in the first quarter. Spark Investment Management LLC now owns 393,300 shares of the biopharmaceutical company’s stock valued at $5,372,000 after buying an additional 153,800 shares during the period. Clovis Capital Management LP bought a new position in shares of Retrophin during the first quarter valued at approximately $1,677,000. Finally, Geode Capital Management LLC raised its position in shares of Retrophin by 9.7% in the first quarter. Geode Capital Management LLC now owns 262,729 shares of the biopharmaceutical company’s stock valued at $3,588,000 after buying an additional 23,275 shares during the period.
Retrophin Inc. (NASDAQ:RTRX) traded up 1.49% during midday trading on Wednesday, reaching $23.12. 338,299 shares of the company’s stock traded hands. The stock has a market capitalization of $849.22 million, a price-to-earnings ratio of 9.39 and a beta of 1.02. The company’s 50-day moving average price is $20.23 and its 200 day moving average price is $17.47. Retrophin Inc. has a 52 week low of $11.60 and a 52 week high of $24.57.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.30. Retrophin had a net margin of 83.57% and a negative return on equity of 0.52%. The company earned $33.30 million during the quarter, compared to analysts’ expectations of $32.73 million. The firm’s revenue was up 38.2% on a year-over-year basis. On average, equities research analysts expect that Retrophin Inc. will post $0.09 earnings per share for the current year.
Several equities analysts recently commented on RTRX shares. Leerink Swann reaffirmed a “buy” rating and set a $4.00 price target on shares of Retrophin in a research report on Tuesday, June 21st. BMO Capital Markets reiterated a “buy” rating on shares of Retrophin in a research note on Monday, June 20th. Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, JMP Securities reiterated a “buy” rating on shares of Retrophin in a research note on Saturday, July 9th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $27.60.
In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the firm’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $16.24, for a total value of $142,100.00. Following the completion of the transaction, the executive vice president now directly owns 158,334 shares in the company, valued at $2,571,344.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. 2.41% of the stock is currently owned by company insiders.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc. (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.